Listed

Bausch Health Companies Inc.

BHCNYSECIK 885590HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$2.85bnRevenue, Q2 FY2026, three months to 2026-06-30$2.85bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0000885590-26-000107.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Jul 30, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$2.85bnRevenue, Q2 FY2026, three months to 2026-06-30$2.85bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0000885590-26-000107.Report this figure+12.7% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin25.9%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $740.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-30, accession 0000885590-26-000107.Revenue: $2.85bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0000885590-26-000107.Report this figure+8.4 pts on a year earlier
  • Net margin9.0%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $258.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0000885590-26-000107.Revenue: $2.85bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0000885590-26-000107.Report this figure+3.2 pts on a year earlier
  • Diluted EPS$0.68Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.68 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0000885590-26-000107.Report this figure+70.0% on a year earlier
  • Free cash flow$593.0mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $670.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0000885590-26-000107. Derived: 6-month figure less the 3-month figure.Capital expenditure: $77.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-30, accession 0000885590-26-000107. Derived: 6-month figure less the 3-month figure.Report this figure+212.1% on a year earlier

Last eight quarters

Full statements
Revenue$2.85bnOperating margin 25.9%
Diluted EPS$0.68, Q2 FY2026
Free cash flow$593.0m, Q2 FY2026
Bausch Health Companies Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m2,510Revenue, Q3 FY2024, three months to 2024-09-30$2.51bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0000885590-25-000051.Report this figure2,559Revenue, Q4 FY2024, three months to 2024-12-31$2.56bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-19, accession 0000885590-26-000023. Derived: 12-month figure less the 9-month figure.Report this figure2,259Revenue, Q1 FY2025, three months to 2025-03-31$2.26bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0000885590-26-000053.Report this figure2,530Revenue, Q2 FY2025, three months to 2025-06-30$2.53bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0000885590-26-000107.Report this figure2,681Revenue, Q3 FY2025, three months to 2025-09-30$2.68bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0000885590-25-000051.Report this figure2,796Revenue, Q4 FY2025, three months to 2025-12-31$2.80bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-19, accession 0000885590-26-000023. Derived: 12-month figure less the 9-month figure.Report this figure2,524Revenue, Q1 FY2026, three months to 2026-03-31$2.52bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0000885590-26-000053.Report this figure2,852Revenue, Q2 FY2026, three months to 2026-06-30$2.85bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0000885590-26-000107.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%12.7%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $318.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-30, accession 0000885590-25-000051.Revenue: $2.51bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0000885590-25-000051.Report this figure21.8%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $558.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-19, accession 0000885590-26-000023. Derived: 12-month figure less the 9-month figure.Revenue: $2.56bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-19, accession 0000885590-26-000023. Derived: 12-month figure less the 9-month figure.Report this figure12.2%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $276.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-30, accession 0000885590-26-000053.Revenue: $2.26bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0000885590-26-000053.Report this figure17.5%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $444.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-30, accession 0000885590-26-000107.Revenue: $2.53bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0000885590-26-000107.Report this figure23.1%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $619.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-30, accession 0000885590-25-000051.Revenue: $2.68bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0000885590-25-000051.Report this figure17.0%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $474.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-19, accession 0000885590-26-000023. Derived: 12-month figure less the 9-month figure.Revenue: $2.80bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-19, accession 0000885590-26-000023. Derived: 12-month figure less the 9-month figure.Report this figure(37.6%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$950.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-30, accession 0000885590-26-000053.Revenue: $2.52bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0000885590-26-000053.Report this figure25.9%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $740.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-30, accession 0000885590-26-000107.Revenue: $2.85bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0000885590-26-000107.Report this figure
Net margin%(3.4%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$85.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-30, accession 0000885590-25-000051.Revenue: $2.51bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0000885590-25-000051.Report this figure3.6%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $93.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-19, accession 0000885590-26-000023. Derived: 12-month figure less the 9-month figure.Revenue: $2.56bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-19, accession 0000885590-26-000023. Derived: 12-month figure less the 9-month figure.Report this figure(2.6%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$58.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-04-30, accession 0000885590-26-000053.Revenue: $2.26bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0000885590-26-000053.Report this figure5.8%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $148.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0000885590-26-000107.Revenue: $2.53bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0000885590-26-000107.Report this figure6.7%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $179.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-30, accession 0000885590-25-000051.Revenue: $2.68bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0000885590-25-000051.Report this figure(4.0%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$112.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-19, accession 0000885590-26-000023. Derived: 12-month figure less the 9-month figure.Revenue: $2.80bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-19, accession 0000885590-26-000023. Derived: 12-month figure less the 9-month figure.Report this figure(56.4%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$1.42bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-04-30, accession 0000885590-26-000053.Revenue: $2.52bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0000885590-26-000053.Report this figure9.0%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $258.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0000885590-26-000107.Revenue: $2.85bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0000885590-26-000107.Report this figure
Diluted EPS$ per share(0.23)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-30, accession 0000885590-25-000051.Report this figurenot reported (Diluted EPS not reported)(0.16)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-30, accession 0000885590-26-000053.Report this figure0.40Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.40 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0000885590-26-000107.Report this figure0.48Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.48 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-30, accession 0000885590-25-000051.Report this figurenot reported (Diluted EPS not reported)(3.82)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$3.82 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-30, accession 0000885590-26-000053.Report this figure0.68Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.68 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0000885590-26-000107.Report this figure
Free cash flow$m334Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $405.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-30, accession 0000885590-25-000051. Derived: 9-month figure less the 6-month figure.Capital expenditure: $71.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-30, accession 0000885590-25-000051. Derived: 9-month figure less the 6-month figure.Report this figure495Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $601.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-19, accession 0000885590-26-000023. Derived: 12-month figure less the 9-month figure.Capital expenditure: $106.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-19, accession 0000885590-26-000023. Derived: 12-month figure less the 9-month figure.Report this figure96.0Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $211.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-30, accession 0000885590-26-000053.Capital expenditure: $115.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-30, accession 0000885590-26-000053.Report this figure190Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $289.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0000885590-26-000107. Derived: 6-month figure less the 3-month figure.Capital expenditure: $99.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-30, accession 0000885590-26-000107. Derived: 6-month figure less the 3-month figure.Report this figure314Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $405.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-30, accession 0000885590-25-000051. Derived: 9-month figure less the 6-month figure.Capital expenditure: $91.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-30, accession 0000885590-25-000051. Derived: 9-month figure less the 6-month figure.Report this figure403Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $495.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-19, accession 0000885590-26-000023. Derived: 12-month figure less the 9-month figure.Capital expenditure: $92.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-19, accession 0000885590-26-000023. Derived: 12-month figure less the 9-month figure.Report this figure121Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $230.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-30, accession 0000885590-26-000053.Capital expenditure: $109.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-30, accession 0000885590-26-000053.Report this figure593Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $670.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0000885590-26-000107. Derived: 6-month figure less the 3-month figure.Capital expenditure: $77.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-30, accession 0000885590-26-000107. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$10.27bnOperating margin 17.7%
Diluted EPS$0.42, FY2025
Free cash flow$1.00bn, FY2025
Bausch Health Companies Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$bn8.4Revenue, FY2021, twelve months to 2021-12-31$8.43bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0000885590-24-000011.Report this figure8.1Revenue, FY2022, twelve months to 2022-12-31$8.12bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-20, accession 0000885590-25-000007.Report this figure8.8Revenue, FY2023, twelve months to 2023-12-31$8.76bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-19, accession 0000885590-26-000023.Report this figure9.6Revenue, FY2024, twelve months to 2024-12-31$9.63bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-19, accession 0000885590-26-000023.Report this figure10.3Revenue, FY2025, twelve months to 2025-12-31$10.27bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-19, accession 0000885590-26-000023.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%5.3%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $450.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-22, accession 0000885590-24-000011.Revenue: $8.43bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0000885590-24-000011.Report this figure5.6%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $454.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-20, accession 0000885590-25-000007.Revenue: $8.12bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-20, accession 0000885590-25-000007.Report this figure11.0%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $963.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-19, accession 0000885590-26-000023.Revenue: $8.76bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-19, accession 0000885590-26-000023.Report this figure16.1%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $1.55bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-19, accession 0000885590-26-000023.Revenue: $9.63bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-19, accession 0000885590-26-000023.Report this figure17.7%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $1.81bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-19, accession 0000885590-26-000023.Revenue: $10.27bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-19, accession 0000885590-26-000023.Report this figure
Net margin%(11.2%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$948.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-22, accession 0000885590-24-000011.Revenue: $8.43bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0000885590-24-000011.Report this figure(2.8%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$225.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-20, accession 0000885590-25-000007.Revenue: $8.12bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-20, accession 0000885590-25-000007.Report this figure(6.8%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$592.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-19, accession 0000885590-26-000023.Revenue: $8.76bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-19, accession 0000885590-26-000023.Report this figure(0.5%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$46.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-19, accession 0000885590-26-000023.Revenue: $9.63bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-19, accession 0000885590-26-000023.Report this figure1.5%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $157.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-19, accession 0000885590-26-000023.Revenue: $10.27bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-19, accession 0000885590-26-000023.Report this figure
Diluted EPS$ per share(2.64)Diluted EPS, FY2021, twelve months to 2021-12-31−$2.64 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-22, accession 0000885590-24-000011.Report this figure(0.62)Diluted EPS, FY2022, twelve months to 2022-12-31−$0.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-20, accession 0000885590-25-000007.Report this figure(1.62)Diluted EPS, FY2023, twelve months to 2023-12-31−$1.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-19, accession 0000885590-26-000023.Report this figure(0.13)Diluted EPS, FY2024, twelve months to 2024-12-31−$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-19, accession 0000885590-26-000023.Report this figure0.42Diluted EPS, FY2025, twelve months to 2025-12-31$0.42 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-19, accession 0000885590-26-000023.Report this figure
Free cash flow$bn1.2Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $1.43bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-22, accession 0000885590-24-000011.Capital expenditure: $269.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-22, accession 0000885590-24-000011.Report this figure(0.9)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$728.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-20, accession 0000885590-25-000007.Capital expenditure: $218.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-20, accession 0000885590-25-000007.Report this figure0.8Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $1.03bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-19, accession 0000885590-26-000023.Capital expenditure: $215.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-19, accession 0000885590-26-000023.Report this figure1.3Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $1.60bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-19, accession 0000885590-26-000023.Capital expenditure: $337.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-19, accession 0000885590-26-000023.Report this figure1.0Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $1.40bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-19, accession 0000885590-26-000023.Capital expenditure: $397.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-19, accession 0000885590-26-000023.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Bausch Health Companies Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
PAULSON & CO. INC.2026-06-30$361.2m73,255,869Unchanged
GOLDENTREE ASSET MANAGEMENT LP2026-06-30$170.7m34,665,731Unchanged
ROYAL BANK OF CANADA2026-06-30$53.4m10,832,582Reduced−530,916
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND2026-06-30$39.4m8,000,000Unchanged
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$36.8m7,465,468Added+61,709
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$33.2m4,803,485Added+574,614
GOLDMAN SACHS GROUP INC2026-06-30$30.7m6,225,131Added+1,017,165
MFN Partners Management, LP2026-06-30$29.6m6,000,000Unchanged
Kohlberg Kravis Roberts & Co. L.P.2026-06-30$25.8m5,235,000Unchanged
ING GROEP NV2026-06-30$24.6m5,000,000Unchanged

Recent filings

All 2,156 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Bausch Health Companies Inc., recent filings
FiledFormWhat it isAccession number
2026-07-3020:11 ET10-QQuarterly reportPeriod 2026-06-300000885590-26-000107
2026-07-2920:11 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000885590-26-000105
2026-07-0120:23 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0000885590-26-000089
2026-05-1920:18 ET8-K5.07 Shareholder vote results0000885590-26-000057
2026-04-3022:12 ET10-QQuarterly reportPeriod 2026-03-310000885590-26-000053
2026-04-2920:10 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000885590-26-000051
2026-04-0820:05 ETDEF 14AProxy statementPeriod 2026-05-190001140361-26-013816
2026-03-0222:17 ET8-K5.02 Departure or appointment of officers or directors0001193125-26-085755
2026-02-1923:10 ET10-KAnnual reportPeriod 2025-12-310000885590-26-000023
2026-02-1821:12 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000885590-26-000020

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 19, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
885590
Tickers
BHC
Exchange
NYSE
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
NJ
Filer category
Large accelerated filer
Former names
Valeant Pharmaceuticals International, Inc. (to 2018-07-03); BIOVAIL Corp (to 2010-09-27); BIOVAIL CORP INTERNATIONAL (to 2010-04-07); BIOVAIL CORPORATION INTERNATIONAL (to 2001-01-05)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:27 ET. Listed shows no prices and gives no investment advice.